Enzymatica (ENZY) investor relations material

Company overview and leadership

• Recently appointed CEO brings entrepreneurial experience and a track record in consumer health and global product launches.

• Focus on developing self-care products using a patented enzyme platform derived from deep-sea cod.

• Flagship product ColdZyme is positioned as a next-generation cold treatment with international ambitions.

Product innovation and scientific evidence

• ColdZyme targets the cause of colds by reducing viral load, not just symptoms, with a unique mechanism.

• Clinical studies show ColdZyme reduces viral load by 94% and shortens illness duration by up to 50%.

• Product is supported by independent, double-blind, placebo-controlled studies, providing strong scientific credibility.

• High customer satisfaction and repeat purchase rates, with over 90% in both metrics.

Market potential and growth strategy

• The global OTC cold market is valued at $35–45 billion, with significant unmet needs for evidence-based, natural products.

• ColdZyme has achieved over 25% growth in Sweden and a 99% repurchase rate, with further domestic potential.

• Expansion strategy includes growing in current markets, building international partnerships, and entering new markets via regulatory approvals.

• MDR class III certification enables sales in over 30 European countries.

• Focus markets for expansion include Europe, Canada, Japan, and the Middle East.